# asieris

**Canonical:** https://apis.io/providers/asieris/  
**Website:** https://asieris.cn  
**APIs profiled:** 0

Asieris Pharmaceuticals is a China-based biopharmaceutical company developing innovative therapies in genitourinary tumors and women's health. Its focus areas span urologic oncology (bladder cancer diagnosis and treatment), women's health, and breast and gynecologic oncology, with marquee assets Vesique (APL-1202) for bladder cancer and Cevira (APL-1702), a non-invasive photodynamic therapy for cervical precancerous lesions. The company runs three proprietary R&D platforms (TIMN, TAIDD, DDC). It was surfaced as a portfolio company of Qiming and added to the API Evangelist network; as a biopharma company it publishes no public developer API surface.

## Kin Score — 10.5 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 10.5).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 7.1 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

Regulatory layer — **Health**: 17.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Asieris Domain Security** — TLSv1.3 · HSTS · DMARC

## Tags

Company, Pharmaceuticals, Biotechnology, Healthcare, Oncology, Women's Health, Life Sciences

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/asieris/). Scores are computed from the provider's own public artifacts under a published rubric.